• Ibuprofen Workflows for Cancer Research

  2026-08-13

  Build reproducible Ibuprofen experiments around COX inhibition, concentration–response design, apoptosis induction, and cell-cycle profiling. The workflow also adapts a protein–drug interaction strategy from a mubritinib–albumin study, helping researchers separate cellular activity from solubility, vehicle, and distribution artifacts.

• Diphenyleneiodonium Chloride: Redox Assay Guide

  2026-08-13

  Diphenyleneiodonium chloride, or DPI, is a versatile perturbation tool for separating NADH oxidase, nitric oxide synthase, cytochrome P450 reductase, and GPR3-linked cAMP effects. This workflow connects DPI-based redox experiments with the iron, ROS, and ferroptosis framework reported in citrus canker research while emphasizing controls that prevent overinterpretation.

• Prochlorperazine-Induced Neuroleptic Malignant Syndrome

  2026-08-12

  This case report documents neuroleptic malignant syndrome after standard-dose prochlorperazine in a 76-year-old man, emphasizing that diagnosis can remain clinically compelling despite limited or delayed laboratory abnormalities. The report also illustrates how medication history, neurological examination, exclusion of mimics, and prompt benzodiazepine- and amantadine-based treatment can guide recovery.

• Low-Molecular Weight Inhibitors of Complement

  2026-08-12

  The reference review explains why complement factor B and factor D are attractive targets for selectively suppressing alternative-pathway amplification. It connects pathway biochemistry, medicinal chemistry, pharmacology, and early clinical translation while highlighting how orally available inhibitors can support research and treatment development across complement-mediated diseases.

• Sulfo-Cy5 Carboxylic Acid in Nano-Adjuvant Imaging

  2026-08-11

  Sulfo-Cy5 carboxylic acid brings aqueous compatibility and near-infrared signal to workflows that track proteins, peptides, and nanoparticle-associated cargo. Its sulfonated structure can reduce dye aggregation, while the reference nano-adjuvant study provides a practical framework for studying sustained release and intestinal targeting.

• NF449 and Selective Platelet P2X1 Blockade

  2026-08-11

  The reference study established NF449 as a comparatively selective antagonist of the platelet P2X1 receptor and used complementary human platelet and mouse thrombosis models to connect receptor blockade with reduced platelet activation. Its findings show that P2X1 contributes to collagen-driven aggregation and thrombus formation, while also demonstrating that dose escalation reduces receptor selectivity and may increase translational risk.

• Benzyl Quinolone Carboxylic Acid and M1 Bias

  2026-08-10

  Benzyl Quinolone Carboxylic Acid (BQCA) is more than a selective M1 probe: it can reveal how receptor state, GRK recruitment, and assay timing shape acetylcholine receptor signaling. This guide translates recent BRET findings into practical experimental decisions for cognitive and Alzheimer’s disease research.

• Applied mCherry mRNA Workflows for Cell Assays

  2026-08-09

  EZ Cap™ mCherry mRNA provides a Cap 1, modified-nucleotide reporter for tracking delivery, localization, and fluorescent protein expression in living cells. This guide connects practical cell-assay setup with nanoparticle loading lessons from a kidney-targeted mRNA study, while separating validated product attributes from workflow starting points.

• Iptacopan: Designing Better Complement Assays

  2026-08-08

  Iptacopan (LNP023) offers a precise way to interrogate alternative-pathway amplification. This guide connects factor B pharmacology with assay design, endpoint selection, and translational interpretation across complement activation research.

• Praeruptorin A Suppresses NF-κB in RAW264.7 Cells

  2026-08-07

  This study examines how Praeruptorin A modulates poly(I:C)-induced inflammation in RAW264.7 macrophages, combining transcriptomic screening with molecular validation. Its findings connect Praeruptorin A with reduced inflammatory gene expression and NF-κB pathway activation, while also defining a practical concentration window for in vitro inflammation assays.

• Deferoxamine Mesylate: Strategic Iron Chelation in Translati

  2026-08-07

  This thought-leadership article explores the mechanistic and translational value of Deferoxamine mesylate as an iron-chelating agent, weaving together insights from ferroptosis research, tumor immunity, and hypoxia signaling. By integrating recent discoveries on lipid scrambling and ferroptotic cell death, it provides actionable guidance for researchers optimizing cancer and tissue protection protocols. The discussion spotlights APExBIO’s Deferoxamine mesylate, illustrates protocol parameters, critically compares the competitive landscape, and maps a forward-looking outlook for iron chelation in precision oncology.

• Nystatin (Fungicidin): Protocols, Advanced Uses, and Trouble

  2026-08-06

  Nystatin (Fungicidin) remains a gold-standard antifungal for research, offering robust inhibition of Candida and Aspergillus species across diverse assay formats. This article delivers actionable protocols, experimental enhancements, and troubleshooting strategies—empowering scientists to maximize data quality and reproducibility in antifungal workflows.

• Mechanistic Precision and Strategic Utility of Alfuzosin HCl

  2026-08-06

  This thought-leadership article provides translational researchers with an advanced, evidence-driven perspective on Alfuzosin Hydrochloride (HCl) as a selective α1 adrenoceptor antagonist. Integrating mechanistic depth, experimental best practices, and recent analytical innovations, the discussion positions APExBIO’s Alfuzosin HCl as a cornerstone for benign prostatic hyperplasia (BPH) and lower urinary tract research—offering strategic guidance for protocol optimization, competitive differentiation, and future-focused translational application.

• Annexin-V Detection of Cardiomyocyte Death in Cardiac I/R In

  2026-08-05

  The reference study introduces in vivo recombinant human annexin-V labeling as a sensitive and specific approach for detecting early cardiomyocyte death following myocardial ischemia/reperfusion (I/R) in mice. This methodological advancement enables precise temporal mapping of cell death, providing a robust platform to evaluate cell death–blocking interventions in cardiovascular research.

• (S)-Mephenytoin: Next-Generation CYP2C19 Substrate in Human

  2026-08-05

  (S)-Mephenytoin emerges as a pivotal CYP2C19 substrate for high-fidelity pharmacokinetic research, especially in organoid-based human models. This article explores advanced applications and experimental strategies that set new benchmarks in drug metabolism studies.

8672 records 9/579 page Previous Next First page 上5页 678910 下5页 Last page